口服氨甲环酸治疗中重度黄褐斑的随机双盲安慰剂对照研究
该单中心随机、安慰剂对照、双盲研究纳入44例中重度黄褐斑患者,口服氨甲环酸250 mg或安慰剂每日两次共3个月,随后仅用防晒3个月。3个月时氨甲环酸组mMASI评分下降49%,对照组下降18%;停药3个月后两组分别较基线下降26%和19%。口服氨甲环酸对中重度黄褐斑似有效且副作用轻微。
要点
- 口服氨甲环酸250 mg每日两次共3个月可显著改善中重度黄褐斑的mMASI评分
- 严重黄褐斑患者的改善程度优于中度患者
- 停药3个月后疗效部分维持,两组均未报告严重不良事件
核心结论
- 口服氨甲环酸对中重度黄褐斑似为有效治疗,副作用轻微。
研究设计与样本
- 随机、安慰剂对照、双盲单中心研究;44例中重度黄褐斑患者入组,39例完成研究;口服氨甲环酸250 mg或安慰剂胶囊每日两次共3个月,随后仅用防晒3个月。
主要发现
- 治疗3个月时氨甲环酸组mMASI评分下降49%,对照组下降18%。
- 严重黄褐斑患者的改善程度大于中度黄褐斑患者。
- 停药3个月后氨甲环酸组mMASI评分较基线下降26%,安慰剂组下降19%。
- 两组均未报告严重不良事件。
关键数值与推荐
- 口服氨甲环酸剂量为250 mg,每日两次,疗程3个月。
- 主要结局指标为改良黄褐斑面积和严重度指数(mMASI)评分。
临床怎么用
- 对中重度黄褐斑患者可考虑口服氨甲环酸250 mg每日两次治疗3个月,并配合防晒,需注意研究人群以西班牙裔女性为主。
局限性
- 单中心研究,入组患者以西班牙裔女性为主。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Melasma is a common pigmentary disorder that is often difficult to treat. Tranexamic acid (TA) has emerged as a promising treatment for melasma; however, few controlled studies exist. OBJECTIVE: To determine the efficacy of oral TA in patients with moderate-to-severe melasma. METHODS: Patients with moderate-to-severe melasma were treated with 250 mg of TA or placebo capsules twice daily for 3 months and sunscreen followed by 3 months of treatment with sunscreen only. The primary outcome measure was the modified Melasma Area and Severity Index (mMASI) score. RESULTS: A total of 44 patients were enrolled and 39 completed the study. At 3 months, there was a 49% reduction in mMASI score in the TA group versus 18% in the control group. Patients with severe melasma improved more than those with moderate melasma. Three months after treatment was stopped, there was a 26% reduction in mMASI score in the TA group compared with the baseline visit versus a 19% reduction in the placebo arm. No serious adverse events were noted in either group. LIMITATIONS: Single-center study enrolling predominantly Hispanic women. CONCLUSIONS: Oral TA appears to be an effective treatment for moderate-to-severe melasma with minimal side effects.
引用
- Del Rosario E, Florez-Pollack S, Zapata L, et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. J Am Acad Dermatol. 2017. PMID: 28987494. doi:10.1016/j.jaad.2017.09.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。